Atossa Therapeutics, INC. (ATOS) — 8-K Filings

All 8-K filings from Atossa Therapeutics, INC.. Browse 18 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (18)

ATOSSA THERAPEUTICS Files 8-K with Financial Statements — Mar 25, 2026
ATOSSA THERAPEUTICS, INC. filed an 8-K on March 25, 2026, to provide financial statements and exhibits under Item 9.01. This filing includes their 8-K document
Atossa Therapeutics Files 8-K — Dec 4, 2025 Risk: low
On December 4, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No spe
Atossa Therapeutics Files 8-K on Executive Changes — Oct 14, 2025 Risk: medium
Atossa Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointm
Atossa Therapeutics Files 8-K — Sep 26, 2025 Risk: low
On September 26, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or disclosures beyond routine reporting r
Atossa Therapeutics Files 8-K Report — Sep 8, 2025 Risk: low
On September 8, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
Atossa Therapeutics Faces Delisting Concerns — Aug 21, 2025 Risk: high
Atossa Therapeutics, Inc. filed an 8-K on August 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The compa
Atossa Therapeutics Files 8-K for Financial Reporting — Aug 12, 2025 Risk: medium
Atossa Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and e
Atossa Therapeutics Files 8-K on Shareholder Vote Matters — May 12, 2025 Risk: medium
Atossa Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on a submission of matters to a vote of security holders. The earliest event reported was on M
Atossa Therapeutics Files 8-K Report — Apr 7, 2025 Risk: low
On April 7, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific financi
Atossa Therapeutics Files 8-K Report — Mar 12, 2025 Risk: low
On March 11, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
Atossa Therapeutics Faces Delisting Concerns — Feb 24, 2025 Risk: high
Atossa Therapeutics, Inc. filed an 8-K on February 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of Fe
Atossa Therapeutics Files 8-K — Feb 4, 2025 Risk: low
On January 30, 2025, Atossa Therapeutics, Inc. filed an 8-K report to disclose other events and financial statements. The filing does not contain specific detai
Atossa Therapeutics Files 8-K with Financials — Dec 10, 2024 Risk: low
On December 10, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpora
Atossa Therapeutics Enters Material Definitive Agreement — Nov 19, 2024 Risk: medium
On November 19, 2024, Atossa Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement,
Atossa Therapeutics Files 8-K — Nov 4, 2024 Risk: low
On November 4, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial
Atossa Therapeutics Files 8-K: Director Changes & Officer Compensation Updates — Jul 2, 2024 Risk: medium
On June 27, 2024, Atossa Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new dir
Atossa Therapeutics Faces Delisting, Plans Reverse Stock Split — Mar 18, 2024 Risk: high
Atossa Therapeutics, Inc. filed an 8-K on March 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is address
Atossa Therapeutics Files 8-K with Board and Compensation Updates — Mar 12, 2024 Risk: medium
Atossa Therapeutics, Inc. filed an 8-K on March 12, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also i

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX